Evidence map›Paper›PMID 39209292›Full record

ReviewSeminars in thrombosis and hemostasis2025

Clinical, Laboratory, Molecular, and Reproductive Aspects of Combined Deficiency of Factors V and VIII.

Elena Yakovleva, Bin Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Seminars in thrombosis and hemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Elena YakovlevaClinical and Diagnostic Department of Hematology and Hemostasis Disorders, National Medical Research Center for Hematology, Moscow, Russia.
Bin ZhangGenomic Medicine Institute, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio.

Funding

ER-to-Golgi transport of coagulation factors V and VIIIR01HL094505 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI ZHANG, BIN · 2009 to 2022
$5.1M
Developing hemophilia A therapeutics by targeting translational and posttranslational regulation of FVIIIR01HL169427 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI Bin Zhang · 2024 to 2026
$1.5M
NHLBI NIH HHS R01 HL094505NHLBI NIH HHS R01 HL169427
6 · The paper itself

Abstract

Congenital combined deficiency of factor V (FV) and factor VIII (FVIII; F5F8D, OMIM 227300) is a rare hereditary coagulopathy and accounts for approximately 3% of cases of rare coagulation disorders. The prevalence of this disease in the general population is estimated to be 1:1,000,000 and is significantly higher in regions where consanguineous marriages are permitted, such as the Mideast and South Asia. The disease has an autosomal recessive mode of inheritance and therefore occurs with an equal incidence among males and females. Heterozygous mutation carriers usually do not have clinical manifestations. The molecular basis of this disease differs from that of stand-alone congenital deficiencies of FVIII and FV. F5F8D is caused by mutations in either

Indexed as

Factor VFactor V DeficiencyFactor VIIIHemophilia AFemaleHumansMaleMannose-Binding LectinsMembrane ProteinsMutationVesicular Transport ProteinsFactor VFactor VIIILMAN1 protein, humanMannose-Binding LectinsMCFD2 protein, humanMembrane ProteinsVesicular Transport Proteins

Identifiers

PMID39209292
PMCPMC11839339

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.